Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated is a biopharmaceutical royalty company that acquires and creates diversified royalty streams from high-value medicines by deploying capital and licensing technologies. The company primarily invests in and structures royalty interests in mid- to late-stage development and commercial biopharmaceutical products to generate long-duration, non-dilutive cash flows with a lean corporate cost structure. Capital deployment and technology licensing drive long-term growth. Ligand partners capital through royalty purchases, development-stage financing arrangements, and acquisitions of companies or assets with embedded royalty rights to create cash-flowing royalties. In addition to royalty investment activities, Ligand operates two infrastructure-light, royalty-generating platform technologies: Captisol® and NITRICIL®. These technologies have existing royalty streams and potential for incremental royalties through partner-driven development and commercialization. Revenue is primarily generated from royalties on sales of products commercialized by partners, supplemented by Captisol material sales and contract revenue from license fees and milestone payments. Ligand partners with biopharmaceutical companies for late-stage development, regulatory execution, and commercialization, while focusing on capital deployment, portfolio construction, and risk management, leveraging partners' infrastructure to avoid high costs. Ligand is a biopharmaceutical royalty aggregator, focusing on disciplined capital allocation to differentiated late-stage assets and operating royalty-generating, infrastructure-light platform technologies. The company has 12 major commercial stage royalty assets, which comprise the majority of its royalty revenue. Ligand maintains a portfolio of more than 90 additional commercial and development-stage programs. In 2022, Ligand refined its strategy to focus on a more efficient, high margin, low infrastructure version of its historical model.